SAUDI-PAYMENTS
10.11.2020 13:53:06 CET | Business Wire | Press release
As Saudi Arabia’s national payments infrastructure operator, Saudi Payments has the task of driving the Kingdom’s digital transformation towards a less dependent on cash society. Its aim, under the Kingdom’s Vision 2030 roadmap, is to ensure 70% of all transactions in the country are digital by 2030, and its secret weapon towards achieving this, is through digital and mobile payments (utilizing Near Field Communication “NFC” technology within physical cards and mobile devices).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005684/en/
Introduced only four years ago, mobile and NFC payments have rapidly become the payment of choice for a largely young, youth and tech savvy Saudi and non-Saudi citizens within the society. The rate of growth has been phenomenal, increasing from 97 million transactions in September 2019, to over 266 million contactless transactions with a value of SAR 27.5 billion. That represents 174% increase comparing to same period in 2019.
The Saudi population is young, in a nation of 35 million people, two thirds are under the age of 35. The Kingdom is also one of the highest users of mobile phones in the world, with over 28 million registered smartphones. The Millennials and Gen Z have grown up in a digital age where they expect to have technology to their fingertips to make payments. “Cash is fast” terminology is becoming a phase of the past.
There are currently over 22 million NFC mada cards in circulation in the Kingdom. In the third quarter of 2020, mobile payments represented 24% of all POS payments, an increase of 567% compared with 2019.
Saudi Payments Managing Director Fahad Al-Akeel said: “The growth in digital and mobile payments has outstripped expectation, Saudi Payments strategy is to enrich the Kingdom’s digital and mobile payment environment and make it more competitive. Our aim is to support the National Digital Transformation under Vision 2030 by enabling the Kingdom of Saudi Arabia to become essentially a less dependent on cash society during the next ten years, if not even achieved beforehand.
However, the speed with which the technology has been adopted has surpassed all expectation. In September 2020 91% of transactions were contactless, compared with 66% in 2019. There are also now over 614K POS terminals across the country, 96% of which are NFC enabled.”
Fahad Al-Akeel acknowledges and emphasizes that COVID-19 has had a positive impact on speeding up the transition, “The huge growth this year in digital and mobile payments could be attributed to COVID-19 and cardholders increasingly turning to online shopping and preferring to use cards and mobile at point of sales “POS” instead of cash. The result has meant we have exceeded all forecasts, with 25% mobile Payments Volume share vs overall POS Volume as of September 2020, compared to 8% in September 2019, an overall increase of 495%.
Saudi Payments developed its universal mobile payments infrastructure in 2018, in connection with all card issuers in the Kingdom, which rapidly lead to the introduction of NFC based payment solutions such as mada Pay and Apple Pay. The overwhelming success of the infrastructure means further OEM and international Pays are anticipated to come on line in the near future.
More recent developments have included an NFC limit/CDCVM/CVM/ PIN free which is applicable on physical NFC mada cards. The single transaction limit on physical cards and mada pay was increased in March 2020 from SAR 100 to SAR 300, in order to minimize the chance of COVID-19 infection and increase the share of contactless payments by simply tapping the card or mobile device without the need of a PIN entry at the POS terminal.
These multiple steps have collectively made NFC a cultural phenomenon which could easily see the Kingdom achieve its Vision 2030 goal of creating a cashless society well before 2030.
Saudi Payments is a fully owned subsidiary of the Saudi Arabian Monetary Authority (SAMA)
About Saudi Payments
Saudi Payments was established in 1991 to operate and develop all major national payment systems.
Since its establishment, it has played a vital role in enabling the public and private sectors to connect with domestic and international payment services, helping to develop the Kingdom’s payment infrastructure.
Saudi Payments provides fast, flexible, and safe electronic payment services at low cost, through mada, SADAD and Esal systems, enhancing the national electronic payment infrastructure and reducing cash transactions.
Saudi Payments supports the government’s Financial Sector Development Program, a part of the Kingdom's Vision 2030 Program. Saudi Payments operates to international standards, connecting local and international service providers with payment networks, reducing the need for cash payments.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005684/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom